New Paper Highlights Role of Immune-Stimulating Cells That Shrink Breast Cancer Tumors
BriaCell Therapeutics Corp., an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, published a paper that sheds light on the potentially unique mechanism of action of BriaCell's lead product candidate, Bria-IMT™, in the journal of Frontiers in Immunology, the 5th most cited journal in Immunology.
View full press release